Drug
Odetiglucan
Odetiglucan is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/1)
Active Trials
2(67%)
Terminated
1(33%)
Phase Distribution
Ph phase_1
1
33%
Ph phase_2
2
67%
Phase Distribution
1
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Terminated(1)
Detailed Status
Recruiting2
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
0.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (33.3%)
Phase 22 (66.7%)
Trials by Status
recruiting267%
terminated133%
Recent Activity
2 active trials
Showing 3 of 3
recruitingphase_2
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
NCT07199764
recruitingphase_2
Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma
NCT07082439
terminatedphase_1
A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT05484011
Clinical Trials (3)
Showing 3 of 3 trials
NCT07199764Phase 2
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
NCT07082439Phase 2
Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma
NCT05484011Phase 1
A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3